

Elizabeth Jane Phillips

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6043573/publications.pdf>

Version: 2024-02-01

231
papers

17,801
citations

20817

60
h-index

16183

124
g-index

241
all docs

241
docs citations

241
times ranked

19127
citing authors

#	ARTICLE	IF	CITATIONS
1	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	27.0	1,668
2	HLA-B*5701 Screening for Hypersensitivity to Abacavir. <i>New England Journal of Medicine</i> , 2008, 358, 568-579.	27.0	1,665
3	Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. <i>Science</i> , 2020, 370, 89-94.	12.6	1,036
4	T cells from patients with Parkinson's disease recognize α -synuclein peptides. <i>Nature</i> , 2017, 546, 656-661.	27.8	618
5	SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. <i>Cell</i> , 2022, 185, 847-859.e11.	28.9	590
6	Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4180-4185.	7.1	451
7	Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. <i>Cell Reports Medicine</i> , 2021, 2, 100204.	6.5	437
8	High Sensitivity of Human Leukocyte Antigen-B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients. <i>Clinical Infectious Diseases</i> , 2008, 46, 1111-1118.	5.8	384
9	Antibiotic allergy. <i>Lancet</i> , 2019, 393, 183-198.	13.7	358
10	Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9959-9964.	7.1	354
11	mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1423-1437.	3.8	351
12	Maintaining Safety with SARS-CoV-2 Vaccines. <i>New England Journal of Medicine</i> , 2021, 384, 643-649.	27.0	330
13	Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. <i>Aids</i> , 2005, 19, 97-99.	2.2	282
14	Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1533-1540.e8.	3.8	257
15	α -Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. <i>Nature Communications</i> , 2020, 11, 1875.	12.8	239
16	Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	4.7	211
17	Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 219-234.	2.9	185
18	The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 518-534.e1.	2.9	180

#	ARTICLE	IF	CITATIONS
19	Clinical and immunogenetic correlates of abacavir hypersensitivity. <i>Aids</i> , 2005, 19, 979-981.	2.2	169
20	HLA and pharmacogenetics of drug hypersensitivity. <i>Pharmacogenomics</i> , 2012, 13, 1285-1306.	1.3	161
21	Penicillin Allergy. <i>New England Journal of Medicine</i> , 2019, 381, 2338-2351.	27.0	159
22	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. <i>Journal of Virology</i> , 2017, 91, .	3.4	148
23	Controversies in drug allergy: Testing for delayed reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 66-73.	2.9	144
24	Mechanism of isoniazidâ€induced hepatotoxicity: then and now. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1030-1036.	2.4	140
25	Penicillin Allergy Is Not Necessarily Forever. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 82.	7.4	139
26	The challenge of deâ€labeling penicillin allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 273-288.	5.7	136
27	Development and Validation of a Penicillin Allergy Clinical Decision Rule. <i>JAMA Internal Medicine</i> , 2020, 180, 745.	5.1	135
28	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	3.8	134
29	Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. <i>Aids</i> , 2002, 16, 2223-2225.	2.2	129
30	Immuneâ€mediated adverse reactions to vaccines. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2694-2706.	2.4	129
31	The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 182-194.	2.4	123
32	HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 183-192.	2.9	118
33	Improving the Effectiveness of Penicillin Allergy De-labeling. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 365-374.e1.	3.8	113
34	T Cellâ€Mediated Hypersensitivity Reactions to Drugs. <i>Annual Review of Medicine</i> , 2015, 66, 439-454.	12.2	109
35	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, S16-S116.	3.8	107
36	Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 547-563.	3.8	106

#	ARTICLE	IF	CITATIONS
37	Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation. <i>Clinical Infectious Diseases</i> , 2017, 65, 166-174.	5.8	106
38	Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	105
39	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLA-B</i> Genotypes and Phenytoin Dosing: 2020 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 302-309.	4.7	102
40	Successful Translation of Pharmacogenetics into the Clinic. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 1-9.	3.8	101
41	Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1731-1733.e3.	3.8	100
42	Pharmacogenetics of drug hypersensitivity. <i>Pharmacogenomics</i> , 2010, 11, 973-987.	1.3	98
43	Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to "de-labeling". <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 526-537.	3.1	92
44	Drug hypersensitivity in HIV. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2007, 7, 324-330.	2.3	91
45	HLA-DRB1 Alleles Are Associated With Different Magnitudes of Dengue Virus-Specific CD4 ⁺ T-Cell Responses. <i>Journal of Infectious Diseases</i> , 2016, 214, 1117-1124.	4.0	88
46	Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. <i>JAMA Internal Medicine</i> , 2021, 181, 1530.	5.1	84
47	Human CD4 ⁺ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. <i>Journal of Virology</i> , 2017, 91, .	3.4	83
48	Antibiotic Allergy in Pediatrics. <i>Pediatrics</i> , 2018, 141, .	2.1	83
49	Identification of drug-specific public TCR driving severe cutaneous adverse reactions. <i>Nature Communications</i> , 2019, 10, 3569.	12.8	83
50	Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 527-535.	5.8	79
51	Global Assessment of Dengue Virus-Specific CD4 ⁺ T Cell Responses in Dengue-Endemic Areas. <i>Frontiers in Immunology</i> , 2017, 8, 1309.	4.8	77
52	Fever, Rash, and Systemic Symptoms: Understanding the Role of Virus and HLA in Severe Cutaneous Drug Allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 21-33.	3.8	74
53	The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 487-496.	5.8	74
54	Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. <i>Nature Nanotechnology</i> , 2022, 17, 337-346.	31.5	74

#	ARTICLE	IF	CITATIONS
55	Abacavir-Reactive Memory T Cells Are Present in Drug Naïve Individuals. PLoS ONE, 2015, 10, e0117160.	2.5	73
56	Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. European Journal of Clinical Pharmacology, 2005, 61, 1-7.	1.9	70
57	Cephalosporin Allergy: Current Understanding and Future Challenges. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2105-2114.	3.8	69
58	Pathways to improved antibiotic allergy and antimicrobial stewardship practice: The validation of a beta-lactam antibiotic allergy assessment tool. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1063-1065.e5.	3.8	65
59	Mapping the Landscape of Host-Pathogen Coevolution: HLA Class I Binding and Its Relationship with Evolutionary Conservation in Human and Viral Proteins. Journal of Virology, 2011, 85, 1310-1321.	3.4	62
60	Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism. Journal of Allergy and Clinical Immunology, 2017, 139, 1710-1713.e2.	2.9	61
61	The 3 Cs of Antibiotic Allergy—Classification, Cross-Reactivity, and Collaboration. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1532-1542.	3.8	60
62	Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses. PLoS ONE, 2017, 12, e0169086.	2.5	60
63	Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 819-829.e2.	3.8	60
64	Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2916-2920.	5.7	59
65	Comparison of HLA allelic imputation programs. PLoS ONE, 2017, 12, e0172444.	2.5	58
66	Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network. Open Forum Infectious Diseases, 2016, 3, ofw153.	0.9	57
67	The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study. Open Forum Infectious Diseases, 2018, 5, ofy306.	0.9	57
68	Testing for drug hypersensitivity syndromes. Clinical Biochemist Reviews, 2013, 34, 15-38.	3.3	56
69	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alpha herpesviruses. Journal of Immunology, 2016, 196, 2205-2218.	0.8	55
70	Cytomegalovirus (CMV) Epitope-Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects. Journal of Immunology, 2017, 199, 3187-3201.	0.8	55
71	HLA-B*35:01 and Green Tea-Induced Liver Injury. Hepatology, 2021, 73, 2484-2493.	7.3	53
72	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036.	4.7	52

#	ARTICLE	IF	CITATIONS
73	Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1155-1167.e5.	3.8	52
74	Associations Between HLA-DRB1*0102, HLA-B*5801, and Hepatotoxicity During Initiation of Nevirapine-Containing Regimens in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, e55-e57.	2.1	51
75	Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 262-271.e2.	2.9	51
76	Natural health productâ€“HIV drug interactions: a systematic review. <i>International Journal of STD and AIDS</i> , 2005, 16, 181-186.	1.1	48
77	Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. <i>Aids</i> , 2007, 21, 1233-1244.	2.2	48
78	HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. <i>Aids</i> , 2014, 28, 1891-1901.	2.2	48
79	Pharmacogenomics of off-target adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1896-1911.	2.4	48
80	A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 353-357.	1.5	47
81	HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13492-13497.	7.1	47
82	The Combined Utility of Ex-Vivo IFN- γ Release Enzyme-Linked ImmunoSpot Assay and In-Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1287-1296.e1.	3.8	47
83	A review of drug patch testing and implications for HIV clinicians. <i>Aids</i> , 2008, 22, 999-1007.	2.2	45
84	Antibiotic Use After Removal of Penicillin Allergy Label. <i>Pediatrics</i> , 2018, 141, .	2.1	44
85	Anaphylaxis after vaccination in a pediatric patient: further implicating alpha-gal allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 322-324.e2.	3.8	44
86	Risk-stratified Management to Remove Low-Risk Penicillin Allergy Labels in the ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1572-1575.	5.6	44
87	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprimâ€“Sulfamethoxazole Induced Liver Injury. <i>Hepatology</i> , 2021, 73, 268-281.	7.3	43
88	Efavirenz and CYP2B6 Polymorphism: Implications for Drug Toxicity and Resistance. <i>Clinical Infectious Diseases</i> , 2006, 42, 408-410.	5.8	42
89	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 463-486.	9.4	42
90	Children with reported penicillin allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 558-565.	1.0	42

#	ARTICLE	IF	CITATIONS
91	Penicillin allergy label persists despite negative testing. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 815-816.	3.8	41
92	Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. <i>Scientific Reports</i> , 2017, 7, 8653.	3.3	41
93	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.9	41
94	Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2968-2982.	3.8	41
95	External Quality Assessment of <i>HLA-B*5701</i> Reporting: An International Multicentre Survey. <i>Antiviral Therapy</i> , 2007, 12, 1027-1032.	1.0	40
96	Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1416-1419.e3.	3.8	39
97	Efavirenz-Induced Skin Eruption and Successful Desensitization. <i>Annals of Pharmacotherapy</i> , 2002, 36, 430-432.	1.9	38
98	Oral challenge with trimethoprim-sulfamethoxazole in patients with <i>œsulfa</i> antibiotic allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 757-760.e4.	3.8	37
99	COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2135-2138.	3.8	37
100	Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naïve HIV-positive patients. <i>Aids</i> , 2007, 21, 1561-1568.	2.2	36
101	Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. <i>Journal of Immunology</i> , 2019, 203, 84-92.	0.8	36
102	Genotyping for Severe Drug Hypersensitivity. <i>Current Allergy and Asthma Reports</i> , 2014, 14, 418.	5.3	35
103	Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses. <i>Frontiers in Immunology</i> , 2019, 10, 1568.	4.8	35
104	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	2.4	34
105	Genome-wide Study Identifies Association between HLA-B*55:01 and Self-Reported Penicillin Allergy. <i>American Journal of Human Genetics</i> , 2020, 107, 612-621.	6.2	34
106	Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. <i>Pharmacogenomics</i> , 2004, 5, 643-655.	1.3	33
107	The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. <i>Journal of Hepatology</i> , 2018, 69, 1317-1325.	3.7	32
108	Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis. <i>Hepatology International</i> , 2019, 13, 641-648.	4.2	32

#	ARTICLE	IF	CITATIONS
109	An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity. <i>Frontiers in Pharmacology</i> , 2020, 11, 573573.	3.5	32
110	The structural basis of HLA-associated drug hypersensitivity syndromes. <i>Immunological Reviews</i> , 2012, 250, 158-166.	6.0	31
111	Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 14-23.	2.4	31
112	Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 607-615.	4.7	29
113	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 1019-1028.	1.0	29
114	Classifying ADRs “ does dose matter?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 10-12.	2.4	27
115	Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. <i>Clinical Infectious Diseases</i> , 2017, 64, 1198-1203.	5.8	27
116	Severe Delayed Drug Reactions. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 785-815.	1.9	27
117	Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2878-2895.e6.	3.8	27
118	Severe COVID-19 Is Associated With an Altered Upper Respiratory Tract Microbiome. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781968.	3.9	27
119	Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A*32:01 “positive vancomycin-induced DRESS sharing an HLA class II haplotype. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 403-405.	2.9	26
120	Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1830-1837.e15.	2.9	26
121	The Role of In Vivo and Ex Vivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2010-2015.e4.	3.8	26
122	The TCR repertoire of α -synuclein-specific T cells in Parkinson’s disease is surprisingly diverse. <i>Scientific Reports</i> , 2021, 11, 302.	3.3	26
123	Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 816-818.	3.8	25
124	The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1341-1343.e1.	3.8	25
125	Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2 ¹ 30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. <i>Journal of Virology</i> , 2017, 91, .	3.4	24
126	Clindamycin skin testing has limited diagnostic potential. <i>Contact Dermatitis</i> , 2005, 53, 335-338.	1.4	23

#	ARTICLE	IF	CITATIONS
127	Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2151-2153.	3.8	22
128	Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1142-1146.e4.	3.8	22
129	HLA and drug-induced toxicity. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 231-42.	2.8	22
130	Cytokine Profiling in Abacavir Hypersensitivity Patients. <i>Antiviral Therapy</i> , 2008, 13, 281-288.	1.0	22
131	Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 435-444.e13.	3.8	20
132	Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1413-1416.e7.	2.9	19
133	High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2163-2169.	2.4	19
134	Analysis of Skin-Resident Memory T Cells Following Drug Hypersensitivity Reactions. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1442-1445.e4.	0.7	19
135	New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals. <i>Human Immunology</i> , 2020, 81, 300-304.	2.4	19
136	Identification and Characterization of CD4 ⁺ T Cell Epitopes after Shingrix Vaccination. <i>Journal of Virology</i> , 2020, 94, .	3.4	18
137	mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, , .	3.8	18
138	Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement. <i>World Allergy Organization Journal</i> , 2022, 15, 100640.	3.5	18
139	Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. <i>Liver International</i> , 2021, 41, 1884-1893.	3.9	17
140	External quality assessment of HLA-B*5701 reporting: an international multicentre survey. <i>Antiviral Therapy</i> , 2007, 12, 1027-32.	1.0	17
141	Individualization of antiretroviral therapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2011, 5, 1.	0.7	16
142	Urinary Peptides As a Novel Source of T Cell Allergen Epitopes. <i>Frontiers in Immunology</i> , 2018, 9, 886.	4.8	16
143	Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 561-576.	3.1	15
144	Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 390-394.	4.7	15

#	ARTICLE	IF	CITATIONS
145	How antibiotic allergy labels may be harming our most vulnerable patients. <i>Medical Journal of Australia</i> , 2018, 208, 469-470.	1.7	15
146	Visual Genomics Analysis Studio as a Tool to Analyze Multiomic Data. <i>Frontiers in Genetics</i> , 2021, 12, 642012.	2.3	14
147	What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 40-51.	1.0	14
148	HLA-B*5701 and flucloxacillin associated drug-induced liver disease. <i>Aids</i> , 2013, 27, 491-492.	2.2	13
149	Drug-specific upregulation of CD137 on CD8+ T cells aids in the diagnosis of multiple antibiotic toxic epidermal necrolysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 823-826.	3.8	13
150	DrugWAS: Drug-wide Association Studies for COVID-19 Drug Repurposing. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1537-1546.	4.7	13
151	Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and Drug Administration Adverse Event Reporting System. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3208-3211.e1.	3.8	13
152	Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration. <i>Journal of Clinical Investigation</i> , 2018, 128, 2746-2749.	8.2	13
153	Low-risk penicillin allergy delabeling through a direct oral challenge in immunocompromised and/or multiple drug allergy labeled patients in a critical care setting. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1660-1663.e2.	3.8	13
154	The evolving story of human leukocyte antigen and the immunogenetics of peanut allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 471-476.	1.0	12
155	Identifying genetically driven clinical phenotypes using linear mixed models. <i>Nature Communications</i> , 2016, 7, 11433.	12.8	12
156	Genomic testing as a tool to optimise drug therapy. <i>Australian Prescriber</i> , 2017, 40, 101-104.	1.0	12
157	A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 782-789.	2.8	12
158	Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity. <i>PLoS ONE</i> , 2015, 10, e0124878.	2.5	11
159	Varying penicillin allergy testing practices in the United States: A time for consensus. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 791-793.	3.8	11
160	Readiness for PENicillin allergy testing: Perception of Allergy Label (PEN-PAL) survey. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3180-3182.e4.	3.8	11
161	Safety, Efficacy, and Effectiveness of Delabeling in Patients with Multiple Drug Allergy Labels. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 922-928.	3.8	11
162	Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions. <i>Frontiers in Genetics</i> , 2021, 12, 641905.	2.3	11

#	ARTICLE	IF	CITATIONS
163	Janssen COVID-19 vaccine tolerated in 10 patients with confirmed polyethylene glycol allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 859-862.	3.8	11
164	Rapid progress in our understanding of COVID-19 vaccine allergy: A cause for optimism, not hesitancy. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 12-16.	2.9	11
165	Antiviral Drug Allergy. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 645-662.	1.9	10
166	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 496 adults from San Diego, California, USA. <i>Human Immunology</i> , 2018, 79, 821-822.	2.4	10
167	A Review of Î²-Lactam Associated Neutropenia and Implications for Cross-reactivity. <i>Annals of Pharmacotherapy</i> , 2020, 55, 106002802097564.	1.9	10
168	Penicillin allergy labels drive perioperative prophylactic antibiotic selection in orthopedic procedures. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3634-3636.e1.	3.8	10
169	Pharmacogenomic biomarkers in allergy and immunology practice. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 509-512.	2.9	10
170	DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 1421-1430.	4.4	10
171	Association of KIR Genes and MHC Class I Ligands with Atopic Dermatitis. <i>Journal of Immunology</i> , 2021, 207, 1522-1529.	0.8	10
172	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. <i>Pathogens and Immunity</i> , 2021, 6, 27-49.	3.1	10
173	A survey of drug allergy training opportunities in the United States. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 302-304.	3.8	9
174	Skin Testing for Penicillin Allergy: a Review of the Literature. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 21.	5.3	9
175	Immediate and Delayed Hypersensitivity Reactions to Beta-Lactam Antibiotics. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 449-462.	6.5	9
176	Cytokine profiling in abacavir hypersensitivity patients. <i>Antiviral Therapy</i> , 2008, 13, 281-8.	1.0	9
177	<i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. <i>Blood</i> , 2022, 140, 274-284.	1.4	9
178	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 339 adults from Managua, Nicaragua. <i>Human Immunology</i> , 2018, 79, 1-2.	2.4	8
179	Implications of electronic health record transition on drug allergy labels. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 764-766.	3.8	8
180	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysisâ€”Coordinating Research Priorities to Move the Field Forward. <i>JAMA Dermatology</i> , 2022, 158, 607.	4.1	8

#	ARTICLE	IF	CITATIONS
181	Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B. <i>Circulation Research</i> , 2022, 131, 258-276.	4.5	8
182	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 714 adults from Colombo, Sri Lanka. <i>Human Immunology</i> , 2018, 79, 87-88.	2.4	7
183	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester region of the Western Cape province of South Africa. <i>Human Immunology</i> , 2018, 79, 143-144.	2.4	7
184	Delayed hypersensitivity associated with amoxicillin-clavulanate. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2700-2702.	5.7	7
185	Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 1019-28.	1.0	7
186	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 4137-4146.	5.2	7
187	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 100 Luo infants from the Boro area of Nyanza Province, Kenya. <i>Human Immunology</i> , 2017, 78, 325-326.	2.4	6
188	Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 126-131.	4.4	6
189	An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3807-3810.	3.8	6
190	Recognizing Drug Hypersensitivity in Pigmented Skin. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 219-238.	1.9	6
191	IFN- γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2920-2928.e5.	0.7	6
192	Retrospective stratification of cephalosporin allergy label risk using validated penicillin allergy frameworks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2472-2475.e1.	3.8	6
193	Adding the "medicines" back into personalized medicine to improve cancer treatment outcomes. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 929-931.	2.4	5
194	Oral Challenge with Trimethoprim-Sulfamethoxazole in Patients with "Sulfa" Antibiotic Allergy Referred to an Outpatient Drug Allergy Clinic. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB209.	2.9	5
195	Positioning Drug Allergy Delabeling as a Critical Tool for Precision Medicine, Quality Improvement, and Public Health. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2916-2919.	3.8	5
196	High-throughput framework for genetic analyses of adverse drug reactions using electronic health records. <i>PLoS Genetics</i> , 2021, 17, e1009593.	3.5	5
197	Allergic Reactions After COVID-19 Vaccination—Putting Risk Into Perspective. <i>JAMA Network Open</i> , 2021, 4, e2122326.	5.9	5
198	NEW STRATEGIES TO PREDICT AND PREVENT SERIOUS IMMUNOLOGICALLY MEDIATED ADVERSE DRUG REACTIONS. <i>Transactions of the American Clinical and Climatological Association</i> , 2018, 129, 74-87.	0.5	5

#	ARTICLE	IF	CITATIONS
199	HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure. <i>Pharmacogenomics Journal</i> , 2022, 22, 124-129.	2.0	5
200	Persistence of Penicillin Allergyâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1714.	7.4	4
201	The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2556-2561.	3.8	4
202	Adverse Events and Safety of SARS-CoV-2 Vaccines: Whatâ€™s New and Whatâ€™s Next. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2254-2266.	3.8	4
203	Defining Regional Differences in Drugâ€Induced Stevensâ€Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 22-25.	4.7	3
204	Slow graded reintroduction of oxcarbazepine for delayed maculopapular eruption. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 411-412.	1.0	3
205	Prevention and Diagnosis of Severe T-Cell-Mediated Adverse Drug Reactions: Are We There Yet?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 228-230.	3.8	3
206	Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees. <i>Viruses</i> , 2020, 12, 1300.	3.3	3
207	Reply to â€œPEG skin testing for COVID-19 allergyâ€. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1765-1766.	3.8	3
208	Role of pharmacogenomics in T-cell hypersensitivity drug reactions. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 327-334.	2.3	3
209	Reply to â€The safety and efficacy of direct oral challenge in trimethoprim-sulfamethoxazole antibiotic allergyâ€. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3849-3850.	3.8	3
210	Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors. <i>Communications Biology</i> , 2022, 5, 133.	4.4	3
211	Addressing betaâ€lactam allergy: A time for action. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1091-1093.	5.7	3
212	Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	3.8	3
213	A case of coronavirus disease 2019 messenger RNA vaccine tolerance and immune response despite presence of anti-polyethylene glycol antibodies. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 246-248.	1.0	3
214	Highlights from the 2nd Biennial Stevens Johnson syndrome symposium 2019: SJS/TEN from Science to Translation. <i>Ocular Surface</i> , 2020, 18, 483-486.	4.4	2
215	Considerations for cross-reactivity between vancomycin and other glycopeptides. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3233.	3.8	2
216	COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA. <i>Lancet Infectious Diseases</i> , The, 2022, , .	9.1	2

#	ARTICLE	IF	CITATIONS
217	Abacavir Hypersensitivity. , 2007, , 95-104.		1
218	Response to letter regarding article "Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis". British Journal of Clinical Pharmacology, 2014, 78, 931-932.	2.4	1
219	The Influence of Patient Anxiety and Perception on the Effectiveness of Drug Allergy Testing. Journal of Allergy and Clinical Immunology, 2019, 143, AB428.	2.9	1
220	Readiness for Penicillin Allergy de-labeling: Perception of Allergy Label (PenPAL) Survey. Journal of Allergy and Clinical Immunology, 2020, 145, AB343.	2.9	1
221	Genome-Wide Association Study Identifies Variation in <i>ABO</i> As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia. Blood, 2020, 136, 38-39.	1.4	1
222	Single-cell immunopathology of systemic contact allergy associated with corticosteroids. Journal of Dermatological Science, 2022, 105, 137-140.	1.9	1
223	HLA class I drug-T cell receptor interactions in SJS/TEN. Clinical and Translational Allergy, 2014, 4, P2.	3.2	0
224	Immune Mechanisms of Drug Allergy. , 2018, , 27-38.		0
225	Pharmacogenomics of Drug Allergy. , 2018, , 39-51.		0
226	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2095-2096.	3.8	0
227	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2854-2856.	3.8	0
228	Reply to "How important is the second dose of the COVID-19 mRNA vaccine?". Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2537-2539.	3.8	0
229	Antifungal hypersensitivity reactions and cross-reactivity patterns. Current Opinion in Infectious Diseases, 2021, Publish Ahead of Print, 559-572.	3.1	0
230	Future Directions and Unmet Research Needs in Cutaneous Adverse Drug Reactions. , 2019, , 275-282.		0
231	Drug Hypersensitivity: A Glass Half Full. Immunology and Allergy Clinics of North America, 2022, 42, xiii-xiv.	1.9	0